Navigation Links
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Date:7/8/2009

degradation.

DOR anticipates proceeding towards clinical development of an oral form of the peptide hormone drug leuprolide using the LPM(TM) technology. Leuprolide is a synthetic peptide agonist of gonadotropin releasing hormone (GnRh) that is used in treatment of endometriosis in women and prostate cancer in men. In preclinical studies in rats and dogs, DOR has demonstrated that the LPM(TM) technology results in high systemic bioavailability of intestinally absorbed leuprolide. In both animal models, the bioavailability of leuprolide ranged from 20 to 40 percent, compared to 2.2 percent for the control oral solution. Leuprolide is one of the most widely used anti-cancer agents for advanced prostate cancer in men. Injectable forms of leuprolide marketed under tradenames such as Lupron(R) and Eligard(R) had worldwide sales of approximately $1.8 billion in 2006. Injectable leuprolide is also widely used in non-cancer indications, such as endometriosis in women (a common condition in which cells normally found in the uterus become implanted in other areas of the body), uterine fibroids in women (noncancerous growths in the uterus) and central precocious puberty in children (a condition causing children to enter puberty too soon). Leuprolide is currently available only in injectable, injectable depot and subcutaneous implant routes of delivery.

LPM(TM) is thought to promote intestinal absorption through the action of the micelles to open up small channels that allow only molecules of a certain dimension to pass through, excluding extremely large molecules, bacteria and viruses. The reverse micelles also structurally prevent the rapid inactivation of peptides by enzymes in the upper gastrointestinal tract. Other sensitive drugs that can be delivered orally with the LPM(TM) system include various classes of drugs such as peptides, nucleic acids and proteins which are degraded in the stomach and small intestine. Corresponding patents in
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
2. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
3. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
4. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
7. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...   Sequenom, Inc. (NASDAQ: SQNM ... analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced a ... "We have great appreciation for Mayo Clinic,s ... welcome the opportunity to partner with the organization,s leading ...
(Date:7/29/2014)... Tough, ultralight foam of atom-thick sheets can be made ... invented at Rice University. , In microscopic images, ... with floors and walls that reinforce each other. The ... and walls of graphene oxide that self-assemble with the ... researchers say the foam could find use in structural ...
(Date:7/29/2014)... 29, 2014  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: IPXL).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... July 29, 2014, Impax Laboratories, Inc. (the "Company") issued ...
(Date:7/29/2014)... Pa. , July 29, 2014  Discovery ... dedicated to advancing a new standard of respiratory ... results on August 5, 2014 before the open ... The Company will host a live teleconference and ... During the conference call, Discovery Labs, management will ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
... Dec. 21, 2011  BioStorage Technologies, a global provider of ... logistics for the bioscience industry, is pleased to announce ... fundraising campaign to the Susan G. Komen for the ... Cancer Center. The $1,000 donation was presented to the ...
... 2011 Neogen Corporation (NASDAQ: NEOG ) announces ... Results Webcast When:  Thursday, December 22, 2011 @ ... How:  Live over the Internet -- Simply log ... Contact:  Terry Maynard of Neogen Corporation, +1-800-234-5333. ...
... 21, 2011 Acumen Pharmaceuticals announces today the ... Merck & Co., Inc.) of a 2003 agreement, ... exclusive worldwide rights to develop and commercialize anti-ADDL ... Merck,s decision to discontinue this anti-ADDL ...
Cached Biology Technology:BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 2BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 3Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck 2
(Date:7/29/2014)... the first to show that while the impact of ... negative effects may be reduced by maintaining a healthy ... participants who exercised, slept well and ate well had ... healthy lifestyles, even when they had similar levels of ... in the department of psychiatry at UCSF. "It,s very ...
(Date:7/28/2014)... the United States have a circulatory problem of the ... and may even require surgery in serious cases. This ... in turn, limb amputation. , At The University of ... scientists tested a non-surgical preventative treatment in a mouse ... increased blood circulation. Their proof-of-concept study appears in ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... farmers who grow genetically engineered (GE) crops are realizing ... production costs, fewer pest problems, reduced use of pesticides, ... a new report from the National Research Council. ... a main component in Roundup and other commercial weed ...
... levels in crop lands is a key factor that ... according to a paper published in the International ... Current global issues include carbon footprints, water resources and ... growth is often overlooked in the global context. ...
... WASHINGTON, D.C. Scientific breakthroughs in molecular targeting, translational cancer ... than 17,000 scientists from around the world gather at the ... 101st Annual Meeting 2010. "We are now entering ... will have the ability to control this disease in the ...
Cached Biology News:Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective 2Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective 3Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective 4Calculating agriculture's phosphorus footprint 2American Association for Cancer Research hosts 101st Annual Meeting 2010 in Washington, D.C. 2
... pump series combines Harvard Apparatuss best pump mechanism, ... wide range of configuration options. A lookup table ... syringes from all the major manufacturers. A bright, ... pertinent information from across the lab. All models ...
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: surface area 21 cm 2 ...
... ultimate tool for investigating dynamic events in ... have been limited at wavelengths longer than ... transmit in the deep UV. HORIBA Jobin ... a filter-based confocal system (the DynaMic) to ...
... protein crystallography involves using many of the ... The liquid handling requirements are similar to ... crystallography plates have 24 or 48 wells ... For higher throughput, the number of wells ...
Biology Products: